Investors

Press releases

2018/11/21

Medivir nominates MIV-828 as a candidate drug for the treatment of hematological malignancies

Read more
2018/10/26

MEDIVIR AB – INTERIM REPORT JANUARY – SEPTEMBER 2018

Read more
2018/10/19

New data from the MIV-711 phase II program will be presented at the ACR Annual Meeting on October 21

Read more

Presentations

Quarterly report presentations

Events

2019/01/08

The Trout Group Annual Management Access Event

Read more
2019/02/14

Year End Report 2018

Read more
2019/05/09

Annual General Meeting 2019

Read more

Corporate Governance

Medivir Corporate Governance documention.

Annual General Meeting

Documentation from Medivir's Annual General Meetings.